

Engineering of Adenovirus Vectors Containing Heterologous Peptide Sequences in the C Terminus of Capsid Protein IX

Igor P. Dmitriev,¹ Elena A. Kashentseva,¹ and David T. Curiel^{1,2*}

Division of Human Gene Therapy, Departments of Medicine, Pathology, and Surgery,¹ and Gene Therapy Center,² University of Alabama at Birmingham, Birmingham, Alabama 35294-3300

Received 18 December 2001/Accepted 5 April 2002

The utility of the present generation of adenovirus (Ad) vectors for gene therapy applications could be improved by restricting native viral tropism to selected cell types. In order to achieve modification of Ad tropism, we proposed to exploit a minor component of viral capsid, protein IX (pIX), for genetic incorporation of targeting ligands. Based on the proposed structure of pIX, we hypothesized that its C terminus could be used as a site for incorporation of heterologous peptide sequences. We engineered recombinant Ad vectors containing modified pIX carrying a carboxy-terminal Flag epitope along with a heparan sulfate binding motif consisting of either eight consecutive lysines or a polylysine sequence. Using an anti-Flag antibody, we have shown that modified pIXs are incorporated into virions and display Flag-containing C-terminal sequences on the capsid surface. In addition, both lysine octapeptide and polylysine ligands were accessible for binding to heparin-coated beads. In contrast to virus bearing lysine octapeptide, Ad vector displaying a polylysine was capable of recognizing cellular heparan sulfate receptors. We have demonstrated that incorporation of a polylysine motif into the pIX ectodomain results in a significant augmentation of Ad fiber knob-independent infection of CAR-deficient cell types. Our data suggest that the pIX ectodomain can serve as an alternative to the fiber knob, penton base, and hexon proteins for incorporation of targeting ligands for the purpose of Ad tropism modification.

Human adenovirus (Ad) includes at least 47 viral serotypes grouped into six distinct subgroups (A to F) and represents a large family of nonenveloped viruses containing a linear double-stranded DNA genome of approximately 36 kb (26). Ad is composed of multiple copies of 11 structural proteins, 7 of which (II, hexon; III, penton base; IIIa; IV, fiber; VI; VIII; and IX) form the icosahedral capsid, while the other 4 (V, VII, μ , and τ) are packaged with the DNA genome in the viral particle (VP) core (28). Studies of the mechanism of Ad infection have revealed that penton base and fiber proteins are responsible for recognition of cellular receptors and therefore determine viral tropism. Ad infection is initiated by the binding of the globular knob domain of the fiber with the primary cellular receptor (19, 27). A fiber receptor for Ad of subgroups A, C, D, E, and F has been identified as the coxsackievirus group B and Ad receptor, called CAR (3, 24, 29). The major histocompatibility complex-1 α 2 subunit was reported as the cellular receptor for subgroup C Ad (15), in addition to CAR and a sialic acid-containing glycoprotein as a receptor moiety for Ad37 of subgroup D (2). Following binding to the fiber receptor, RGD motifs within penton base interact with $\alpha_v\beta$ integrins and facilitate virus internalization via receptor-mediated endocytosis (13, 21, 32).

Ad is widely used as a vector for both in vitro and in vivo gene delivery due to its ability to infect a variety of cell types (37). However, patterns of viral receptor expression vary between different tissues (10), predicated by their susceptibilities to

Ad infection. The increased knowledge of the Ad capsid structure combined with an understanding of the biology of virus interaction with cellular receptors has facilitated the development of targeted Ad vectors (6, 7). Genetic engineering of Ad capsid proteins to incorporate targeting ligands has been employed to generate Ad vectors with novel viral tropism that can overcome the limited infectivity associated with deficiency of viral receptors (18, 31). Several heterologous peptide ligands have been successfully engineered into the HI loop (8, 23, 36) and C terminus of fiber (33, 35), the L1 loop of hexon (30), and the RGD loop of penton base (34), resulting in markedly increased efficiency of Ad infection in a variety of CAR-deficient cell types. However, the structural properties of the surface-exposed loops of capsid proteins make them suitable only for incorporation of constrained heterologous sequences, and addition of ligands to the C terminus of fiber apparently has size limitations (35).

The present study evaluates the utility of Ad capsid protein IX (pIX) (4, 5) for the purpose of viral tropism modification via genetic incorporation of heterologous peptides. pIX is a minor component of Ad capsid that stabilizes hexon-hexon interactions (11) and is also essential for viral DNA packaging (12). Recent studies have demonstrated that the C terminus of pIX is exposed on the outer surface of the viral capsid (1, 25), suggesting that it could be used as a novel locale for incorporation of targeting ligands. To assess the feasibility of incorporating heterologous sequences into pIX, we engineered Ad vectors encoding recombinant pIX containing either eight consecutive lysines or a polylysine sequence following a C-terminal Flag octapeptide. Here, we demonstrate that modified pIX is incorporated into mature Ad virions and displays Flag-containing carboxy-terminal extensions which are accessible for bind-

* Corresponding author. Mailing address: Division of Human Gene Therapy, Departments of Medicine, Pathology, and Surgery, Gene Therapy Center, University of Alabama at Birmingham, 901 19th St. South, BMR II-508, Birmingham, AL 35294-2172. Phone: (205) 934-8627. Fax: (205) 975-7476. E-mail: David.Curiel@ccc.uab.edu.

AdLuc (pIX wt)

S A L K A S S P P N A V * poly(A) signal

TCTGCCCTGAAGGCTTCTCCCTCCCAATGCGGTT**taaacataataaa**accagactctgttggatttgatcaagcaa*Dra* I**AdLucIXflag** Flag octapeptideV S A D Y K D D D D K *GTTTCTGCCGATTATAAGGATGACGATGACAAG**taaacataataaa**accagactctgttggatttgatcaagcaa**AdLucIXpK**V S A D Y K D D D D K L A I N K K P D S V W I W I K K K poly(Lys)GTTTCTGCCGATTATAAGGATGACGATGACAAG**CTAGCCATAAATAAAAAACCAGACTCTGTTTGGATTGGATCAAAAAAAAA***Nhe* I**AdLucIX8K**V S A D Y K D D D D K L G S A S A K K K K K K K K K * Lys₈GTTTCTGCCGATTATAAGGATGACGATGACAAG**CTAGGATCCGCAAGAAAAAGAAAAAGAAAAAGAAAAAGtaaacataataaa**

FIG. 1. Schema of Ad pIX modifications. To generate the AdLucIXflag vector, the Flag octapeptide (DYKDDDDK) coding sequence was introduced into the *Dra*I site of the wild-type pIX gene. Introduction of the *Nhe*I site following the Flag coding sequence in AdLucIXpK caused a pIX stop codon deletion and translation through the poly(A) signal, resulting in incorporation of a poly(Lys) tail into the carboxy terminus of pIX. Cloning of the DNA sequence encoding eight consecutive lysines resulted in restoration of the stop codon and incorporation of a Lys₈ peptide into the C terminus of pIX. Modified DNA and protein sequences of pIX are designated by italics. Translated amino acid sequences are presented in capital letters. Restriction sites are underlined, and the poly(A) signal is indicated in boldface. Incorporated Flag, poly(Lys), and Lys₈ peptide sequences are underlined.

nated AdLucIXpK. Incorporation of an *Nhe*I site caused a deletion of the pIX stop codon and should have resulted in translation of mRNA containing a poly(A) tail. To validate this, we carried out reverse transcription-PCR using total mRNA isolated from AdLucIXpK-infected cells as a template. Sequencing of PCR products confirmed the presence of 39 nucleotides, including a poly(A) signal downstream of the Flag coding sequence followed by multiple adenosines (Fig. 1). To derive the AdLucIX8K vector encoding pIX incorporating a carboxy-terminal Flag epitope along with eight consecutive lysines (Lys₈), the corresponding DNA duplex was cloned into the shuttle plasmid *Nhe*I site, restoring the deleted stop codon. Thus, we have constructed three Ad vectors containing a pIX gene modified to introduce heterologous peptide sequences, including the Flag epitope for detection purposes. Both Lys₈ and poly(Lys) incorporated sequences serve as heparin-binding domains known to target Ad vectors to broadly expressed heparan sulfate-containing cellular receptors (33, 35).

The presence of modified pIX in Ad capsid. The incorporation of modified pIX containing heterologous peptides into viral capsids was demonstrated by Western blotting. The virions of AdLucIXflag, AdLucIX8K, and AdLucIXpK purified by CsCl gradient centrifugation were denatured by being boiled, and the capsid proteins were separated by SDS-PAGE. The AdLuc vector containing the wild-type pIX gene was used as a negative control. The probing of electrophoretically resolved viral capsomers of AdLucIXflag and AdLucIX8K using an anti-Flag M2 MAb detected the presence of protein bands with molecular masses of 15.7 and 17.2 kDa, as expected for pIXflag and pIX8K, respectively (Fig. 2). The presence of poly(Lys) sequences in AdLucIXpK capsids was confirmed by the shift of its electrophoretic mobility compared to pIXflag and pIX8K. An increase in the molecular mass of pIXpK by

approximately 3 kDa compared to pIXflag corresponds to an increase in protein length of at least 25 amino acids.

To test if peptides incorporated into modified pIX are displayed on the surfaces of VPs, we performed an ELISA. Purified AdLucIXflag, AdLucIX8K, AdLucIXpK, and control AdLuc virions were immobilized on ELISA plates and probed with an anti-Flag MAb. AdLucIXflag and AdLucIX8K revealed the same level of interaction with the anti-Flag MAb,




FIG. 2. Western blot analysis of pIX-modified Ad vectors. Samples of CsCl-purified AdLuc (pIXwt), AdLucIXflag (pIXflag), AdLucIX8K (pIX8K), and AdLucIXpK (pIXpK) were boiled in Laemmli loading sample buffer and separated by 4 to 20% gradient SDS-PAGE. Electrophoretically resolved viral proteins were transferred to polyvinylidene difluoride membranes, probed with anti-Flag M2 MAb, and detected with secondary alkaline phosphatase-conjugated goat anti-mouse antibodies. The numbers on the left indicate the molecular masses of marker proteins (lane MW) in kilodaltons.




FIG. 3. Presentation of modified pIX C terminus on Ad capsid. Dilutions of CsCl-purified AdLuc, AdLucIXflag, AdLucIX8K, and AdLucIXpK were immobilized on an ELISA plate and probed with anti-Flag M2 MAb. Anti-Flag MAb bound to the VPs was detected with alkaline phosphatase-conjugated secondary antibody. Each point represents the cumulative mean \pm SD of triplicate determinations. Some error bars depicting SDs are smaller than the symbols.

while AdLucIXpK showed somewhat less efficient binding (Fig. 3). These results demonstrate that Flag peptides introduced into the pIX carboxy terminus are accessible for recognition by antibodies, strongly suggesting that both the Flag epitope and downstream peptide sequences are displayed on the surfaces of these recombinant Ad capsids.

Accessibility of pIX-incorporated peptides for binding. We used binding assays to confirm that lysine sequences incorporated into AdLucIX8K and AdLucIXpK are capable of binding heparan sulfates. First, we tested the ability of Lys₈ and poly(Lys) peptides to effect binding of radioactively labeled AdLucIX8K or AdLucIXpK to heparin-coated beads. As shown in Fig. 4A, both viruses demonstrated markedly increased binding to heparin molecules compared to AdLuc and AdLucIXflag control viruses.

To characterize the ability of AdLucIX8K and AdLucIXpK to recognize heparan sulfate-containing cell surface receptors, we carried out binding assays with AU-565 cells in the presence or absence of heparin or Ad5 knob protein. The results presented in Fig. 4B show that AdLucIXpK exhibits a 2.5-fold higher cell-binding efficiency than AdLuc and AdLucIXflag control viruses ($P < 0.001$). In contrast to binding to immobilized heparin, AdLucIX8K did not show any improvement of binding to heparan sulfate cell surface receptors. The presence of free heparin blocked 45% of AdLucIXpK cell binding ($P < 0.001$) but did not affect the binding of the control viruses to the cells. Addition of Ad5 knob blocked 50% of control virus binding ($P < 0.004$) while having relatively little effect (17%; $P = 0.01$) on AdLucIXpK. These data suggest that the poly(Lys) sequence displayed on AdLucIXpK capsid mediates Ad interaction with cellular heparan sulfate receptors, resulting in CAR-independent virus-cell binding.




FIG. 4. Accessibility of pIX-incorporated ligands for binding. (A) Binding of pIX-modified Ad to heparin-coated beads. Suspensions of heparin-coated ceramic beads were incubated with 10^{10} VP (2×10^5 to 8×10^5 cpm) of ³H-labeled AdLuc (pIX wt), AdLucIXflag (pIXflag), AdLucIX8K (pIX8K), and AdLucIXpK (pIXpK). The beads were washed by centrifugation to remove unbound virions, and then bound radioactivity was calculated as a percentage of input radioactivity for each Ad sample. Each bar represents the cumulative mean \pm SD of triplicate determinations. (B) Binding of pIX-modified Ad to AU-565 cells. Aliquots of AU-565 cells (10^6) were preincubated separately with Ad5 knob protein, heparin, or PBS (Virus alone). Samples of radiolabeled AdLuc (pIX wt), AdLucIXflag (pIXflag), AdLucIX8K (pIX8K), and AdLucIXpK (pIXpK) containing 10^{10} VP (2×10^5 to 8×10^5 cpm) were added to the cells and incubated for 1 h at 4°C. Bound radioactivity was determined after washing the cell samples by centrifugation, and the VP/cell ratio was calculated for each Ad vector. Each bar represents the cumulative mean \pm SD of triplicate determinations.

Infection efficiency of pIX-modified Ad vectors. We evaluated whether the ability of AdLucIXpK to bind heparan sulfate-containing receptors would result in improvement of Ad infection of CAR-deficient cell types. Our previous study showed that AU-565, GI-101A, and HUVEC cells are relatively refractory to Ad infection due to the low level of CAR on their surfaces (unpublished data). Using a gene transfer assay, we tested the ability of poly(Lys) displayed by pIX on the viral capsid to mediate Ad infection in the presence or absence of Ad5 knob protein. As illustrated in Fig. 5A, AdLucIXpK dem-




FIG. 5. Infection properties of pIX-modified Ad vectors. (A) Monolayers of GI-101A, AU-565, and HUVEC CAR-deficient cell lines and CAR-positive 293 cells were infected with pIX-modified AdLucIXflag, AdLucIX8K, AdLucIXpK, or control AdLuc vector in the presence or absence of Ad5 knob protein. The levels of luciferase activity were determined in lysates of infected cells 20 h postinfection. The results are presented as the percentages of luciferase activity detected in the cells infected in the presence of Ad5 knob protein calculated with respect to luciferase activity determined in the cells infected in the absence of knob (100%). Each bar represents the cumulative mean \pm SD of triplicate determinations. (B) Cell monolayers were infected with AdLucIXflag, AdLucIX8K, AdLucIXpK, or control AdLuc vectors in the presence or absence of free heparin. The luciferase from cell lysate activities was analyzed 20 h postinfection. The results are presented as the percentages of luciferase activity detected in the cells infected in the presence of free heparin calculated with respect to luciferase activity determined in the absence of heparin (100%). Each bar represents the cumulative mean \pm SD of triplicate determinations.

onstrated 4.3-, 2.8-, and 2.1-fold enhancement of gene transfer to GI-101A, AU-565, and HUVEC cells, respectively, compared to AdLucIXflag control virus in the presence of Ad5 knob protein ($P = 0.02$). There were no significant differences




FIG. 6. Thermostabilities of pIX-modified Ad vectors. Aliquots of AdLucIXflag, AdLucIX8K, AdLucIXpK, or AdLuc vector were incubated at 45°C for different time intervals and then used to infect 293 cells. The results are presented as the percentages of luciferase activity detected in the cells infected with a heat-treated viral sample with respect to luciferase activity determined in the cells infected with untreated virus (100%). Each bar represents the cumulative mean \pm SD of triplicate determinations. Some error bars depicting SDs are smaller than the symbols.

in the levels of gene transfer detected following infection of CAR-positive 293 cells. To confirm that the observed augmentation of CAR-independent infection efficiency was due to the binding of AdLucIXpK to cellular heparan sulfates, we performed gene transfer assays in the presence of free heparin. As can be seen in Fig. 5B, gene transfer mediated by AdLucIXpK was blocked by heparin to a significantly greater extent (30 to 73%, depending on the cell line; $P \leq 0.05$) than that mediated by control Ad vectors. Consistent with our cell-binding assays, AdLucIX8K did not show any augmentation in the level of infectivity.

Thermostabilities of pIX-modified viruses. Since pIX is involved in Ad capsid stabilization and is essential for proper viral DNA packaging, we tested the thermostabilities of pIX-modified Ad vectors to see whether the incorporated peptides affect virion structural integrity. The relative thermostabilities of pIX-modified viruses were compared indirectly by measuring Ad-mediated gene transfer efficiencies following incubation of virions at 45°C. This experiment shows that the level of luciferase expression achieved by AdLucIXpK is reduced two-fold compared to those of AdLucIXflag, AdLucIX8K, and unmodified AdLuc (Fig. 6), indicating a decrease of AdLucIXpK thermostability. This finding is consistent with an increased VP/PFU ratio (220) observed for AdLucIXpK compared to both AdLucIX8K and AdLuc (VP/PFU ratio, 55).

DISCUSSION

To develop a targeted Ad vector, it is necessary both to ablate native viral tropism and to introduce a novel specificity

which will allow targeting of certain cell types otherwise refractory to Ad infection. Ablation of Ad binding to its natural receptors is a prerequisite for the generation of truly targeted Ad vectors and has been addressed recently (16, 17). Mutagenesis of both Ad5 fiber knob and penton has been employed to abrogate CAR- and integrin-dependent viral tropism and to improve the targeting potential of Ad vectors (9). The next step toward the generation of target-specific Ad is to redirect the virus to alternative receptors present on the cells of interest. In this regard, genetic modification of viral capsid proteins to incorporate targeting ligands has proven to be a rational approach for introducing novel cell-specific tropism and overcoming limitations associated with low levels of native receptors. Targeting peptide ligands have been introduced into the HI loop (8, 23, 36) or C terminus of Ad5 fiber protein (33, 35) and the L1 loop of hexon protein (30). Engineered Ad vectors bearing either polylysine (33), RGD, or NGR motifs (8, 23, 30, 35) or a transferrin receptor binding peptide (36) exhibited a marked increase of infection efficiency in a variety of CAR-deficient cell types via recognition of heparan sulfates, integrins, or the transferrin receptor, respectively. The limited number of genetic modifications of Ad capsid achieved so far reflects, in part, the limited availability of exploitable peptide ligands. In this regard, structural properties of the surface-exposed loops in capsid proteins apparently make them suitable only for constrained ligand sequences. Furthermore, carboxy-terminal extensions of fiber protein can affect correct folding of fiber trimers, thus interfering with virus assembly. Therefore, a major improvement in genetic Ad targeting strategies would be the identification of a capsid locale that allows incorporation of heterologous, high-affinity polypeptide ligands.

In this study, we evaluated the utility of pIX, a minor component of the Ad capsid, as an alternative site for ligand incorporation for the purpose of viral tropism modification. pIX functions as a cement protein stabilizing hexon-hexon interactions and is essential for viral DNA packaging. In addition to its structural contribution, pIX exhibits transcription-regulatory properties (25). It was recently shown for Ad serotypes 2, 3, and 5 that the C-terminal region of pIX is located on the virion surface (1, 25). We proposed to exploit this finding for pIX carboxy-terminal incorporation of heterologous polypeptides that could serve as ligands for receptor-specific Ad5 infection. Such incorporation of targeting ligands would ideally be achieved in such a manner as to allow both surface presentation and proper assembly of VPs. To evaluate this concept, we first engineered the AdLucIXflag vector encoding a carboxy-terminal extension of pIX consisting of the Flag octapeptide. We then established the surface localization of the Flag epitope in the context of assembled virions and its accessibility for binding with anti-Flag MAb using affinity column purification (data not shown). Ad vectors, AdLucIX8K and AdLucIXpK, were engineered to encode pIX C-terminal heparin-binding motifs consisting of either eight or multiple consecutive lysines. For detection of modified pIX ectodomain on the outer capsid surface, we placed a Flag peptide upstream of the lysine-containing sequences. The probing of generated viruses with anti-Flag MAb demonstrated that modified pIX is incorporated into viral capsids and displays Flag-containing additions on the surfaces of VPs. Importantly, both

AdLucIX8K and AdLucIXpK were shown to bind heparin immobilized on ceramic beads, demonstrating that the pIX ectodomain displays peptide ligands accessible for binding. However, AdLucIX8K did not reproduce its ability to bind heparan-containing receptors on cellular membranes. These data suggest that the length of the C-terminal extension of pIX is important for positioning the ligand sequence distal to the Ad capsid surface, making it more accessible for interaction with cellular receptors. The use of the Ad fiber knob to inhibit virus-cell binding and subsequent gene transfer to CAR-deficient cell lines revealed significant augmentation of knob-independent infection mediated by AdLucIXpK compared to AdLucIXflag and AdLuc control viruses. On the other hand, both cell binding and gene transfer mediated by AdLucIXpK were blocked by free heparin to a higher degree than for control viruses. The observed augmentation of knob-independent infection achieved by AdLucIXpK is very likely due to the binding of pIX-incorporated polylysine to heparan sulfates on cellular membranes. These results suggest that pIX-mediated presentation of targeting ligands on the surfaces of Ad vector capsids may be compatible with Ad tropism modification strategies. To evaluate whether carboxy-terminal pIX modifications have an impact on the proper assembly of VPs, we tested the relative thermostabilities of generated Ad vectors. Comparison of gene transfer levels achieved by pIX-modified Ad vectors following incubation of virions at 45°C revealed that AdLucIXpK was less stable than AdLucIXflag, AdLucIX8K, and AdLuc. Consistent with a fourfold-increased VP/PFU ratio observed for AdLucIXpK compared to control Ad vectors, this result indicates that carboxy-terminal peptide extensions of pIX can have some impact on virion structural integrity. Considering both positive and negative aspects of pIX modification revealed in this report, we believe that pIX may have utility for genetic modifications of Ad capsid. Our study suggests that the pIX ectodomain may represent an attractive capsid locale, alternative to fiber knob, hexon, and penton base, for ligand incorporation for the purpose of Ad targeting.

ACKNOWLEDGMENTS

We are grateful to Joel N. Glasgow for fruitful discussions and proofreading of the manuscript.

This work was supported by the following grants: N01 C0-97110, P50 CA89019, R01 CA86881, R01 CA74242, R01 CA68245, R01 CA90547, and R01 HL67962 from the National Institutes of Health and the Juvenile Diabetes Foundation to David T. Curiel.

REFERENCES

1. Akalu, A., H. Liebermann, U. Bauer, H. Granzow, and W. Seidel. 1999. The subgenus-specific C-terminal region of protein IX is located on the surface of the adenovirus capsid. *J. Virol.* 73:6182-6187.
2. Arnberg, N., K. Edlund, A. H. Kidd, and G. Wadell. 2000. Adenovirus type 37 uses sialic acid as a cellular receptor. *J. Virol.* 74:42-48.
3. Bergelson, J. M., J. A. Cunningham, G. Droguett, E. A. Kurt-Jones, A. Krithivas, J. S. Hong, M. S. Horwitz, R. L. Crowell, and R. W. Finberg. 1997. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. *Science* 275:1320-1323.
4. Boulanger, P., P. Lemay, G. E. Blair, and W. C. Russell. 1979. Characterization of adenovirus protein IX. *J. Gen. Virol.* 44:783-800.
5. Burnett, R. M. 1985. The structure of the adenovirus capsid. II. The packing symmetry of hexon and its implications for viral architecture. *J. Mol. Biol.* 185:125-143.
6. Curiel, D. T. 2000. Rational design of viral vectors based on rigorous analysis of capsid structures. *Mol. Ther.* 1:3-4.
7. Curiel, D. T. 1999. Strategies to adapt adenoviral vectors for targeted delivery. *Ann. N. Y. Acad. Sci.* 886:158-171.
8. Dmitriev, I., V. Krasnykh, C. R. Miller, M. Wang, E. Kashentseva, G.

- Mikheeva, N. Belousova, and D. T. Curiel. 1998. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. *J. Virol.* **72**:9706–9713.
9. Einfeld, D. A., R. Schroeder, P. W. Roelvink, A. Lizonova, C. R. King, I. Kovesdi, and T. J. Wickham. 2001. Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. *J. Virol.* **75**:11284–11291.
10. Fechner, H., A. Haack, H. Wang, X. Wang, K. Eizema, M. Pauschinger, R. Schoemaker, R. Veghel, A. Houtsmuller, H. P. Schultheiss, J. Lamers, and W. Poller. 1999. Expression of coxsackie adenovirus receptor and alphav integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. *Gene Ther.* **6**:1520–1535.
11. Furciniti, P. S., J. van Oostrum, and R. M. Burnett. 1989. Adenovirus polypeptide IX revealed as capsid cement by difference images from electron microscopy and crystallography. *EMBO J.* **8**:3563–3570.
12. Ghosh-Choudhury, G., Y. Haj-Ahmad, and F. L. Graham. 1987. Protein IX, a minor component of the human adenovirus capsid, is essential for the packaging of full length genomes. *EMBO J.* **6**:1733–1739.
13. Greber, U. F., M. Willetts, P. Webster, and A. Helenius. 1993. Stepwise dismantling of adenovirus 2 during entry into cells. *Cell* **75**:477–486.
14. He, T. C., S. Zhou, L. T. da Costa, J. Yu, K. W. Kinzler, and B. Vogelstein. 1998. A simplified system for generating recombinant adenoviruses. *Proc. Natl. Acad. Sci. USA* **95**:2509–2514.
15. Hong, S. S., L. Karayan, J. Tournier, D. T. Curiel, and P. A. Boulanger. 1997. Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells. *EMBO J.* **16**:2294–2306.
16. Kirby, I., E. Davison, A. J. Beavil, C. P. Soh, T. J. Wickham, P. W. Roelvink, I. Kovesdi, B. J. Sutton, and G. Santis. 2000. Identification of contact residues and definition of the CAR-binding site of adenovirus type 5 fiber protein. *J. Virol.* **74**:2804–2813.
17. Kirby, I., E. Davison, A. J. Beavil, C. P. Soh, T. J. Wickham, P. W. Roelvink, I. Kovesdi, B. J. Sutton, and G. Santis. 1999. Mutations in the DG loop of adenovirus type 5 fiber knob protein abolish high-affinity binding to its cellular receptor CAR. *J. Virol.* **73**:9508–9514.
18. Krasnykh, V. N., J. T. Douglas, and V. W. van Beusechem. 2000. Genetic targeting of adenoviral vectors. *Mol. Ther.* **1**:391–405.
19. Louis, N., P. Fender, A. Barge, P. Kitts, and J. Chroboczek. 1994. Cell-binding domain of adenovirus serotype 2 fiber. *J. Virol.* **68**:4104–4106.
20. Maizel, J. V., Jr., D. O. White, and M. D. Scharff. 1968. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. *Virology* **36**:115–125.
21. Mathias, P., T. Wickham, M. Moore, and G. Nemerow. 1994. Multiple adenovirus serotypes use alpha v integrins for infection. *J. Virol.* **68**:6811–6814.
22. Mittereder, N., K. L. March, and B. C. Trapnell. 1996. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. *J. Virol.* **70**:7498–7509.
23. Mizuguchi, H., N. Koizumi, T. Hosono, N. Utoguchi, Y. Watanabe, M. A. Kay, and T. Hayakawa. 2001. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. *Gene Ther.* **8**:730–735.
24. Roelvink, P. W., A. Lizonova, J. G. Lee, Y. Li, J. M. Bergelson, R. W. Finberg, D. E. Brough, I. Kovesdi, and T. J. Wickham. 1998. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. *J. Virol.* **72**:7909–7915.
25. Rosa-Calatrava, M., L. Grave, F. Puvion-Dutilleul, B. Chatton, and C. Keding. 2001. Functional analysis of adenovirus protein IX identifies domains involved in capsid stability, transcriptional activity, and nuclear reorganization. *J. Virol.* **75**:7131–7141.
26. Shenk, T. 1996. Adenoviridae: the viruses and their replication, p. 2111–2148. *In* B. N. Fields, D. M. Knipe, et al. (ed.), *Fields virology*, 3rd ed., vol. 2. Lippincott-Raven Publishers, Philadelphia, Pa.
27. Stevenson, S. C., M. Rollence, B. White, L. Weaver, and A. McClelland. 1995. Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain. *J. Virol.* **69**:2850–2857.
28. Stewart, P. L. 2002. Adenovirus structure, p. 1–18. *In* D. T. Curiel and J. T. Douglas (ed.), *Adenoviral vectors for gene therapy*. Academic Press, San Diego, Calif.
29. Tomko, R. P., R. Xu, and L. Philipson. 1997. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. *Proc. Natl. Acad. Sci. USA* **94**:3352–3356.
30. Vigne, E., I. Mahfouz, J. F. Dedieu, A. Brie, M. Perricaudet, and P. Yeh. 1999. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. *J. Virol.* **73**:5156–5161.
31. Wickham, T. J. 2000. Targeting adenovirus. *Gene Ther.* **7**:110–114.
32. Wickham, T. J., P. Mathias, D. A. Cheresh, and G. R. Nemerow. 1993. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. *Cell* **73**:309–319.
33. Wickham, T. J., P. W. Roelvink, D. E. Brough, and I. Kovesdi. 1996. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. *Nat. Biotechnol.* **14**:1570–1573.
34. Wickham, T. J., D. M. Segal, P. W. Roelvink, M. E. Carrion, A. Lizonova, G. M. Lee, and I. Kovesdi. 1996. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. *J. Virol.* **70**:6831–6838.
35. Wickham, T. J., E. Tzeng, L. L. Shears II, P. W. Roelvink, Y. Li, G. M. Lee, D. E. Brough, A. Lizonova, and I. Kovesdi. 1997. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. *J. Virol.* **71**:8221–8229.
36. Xia, H., B. Anderson, Q. Mao, and B. L. Davidson. 2000. Recombinant human adenovirus: targeting to the human transferrin receptor improves gene transfer to brain microcapillary endothelium. *J. Virol.* **74**:11359–11366.
37. Zhang, W. W. 1999. Development and application of adenoviral vectors for gene therapy of cancer. *Cancer Gene Ther.* **6**:113–138.